Subscribe to our Email Alerts

Amplia Therapeutics Limited

Amplifying Oncology Treatments

Learn more

Amplia Therapeutics Limited

Focal Adhesion Kinase: A New Target in the Fight Against Cancer

Learn more

Amplia Therapeutics Limited

Focus on Fibrotic Cancers and Fibrosis

Learn more
 
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
To view the latest Amplia Therapeutics Limited's Investor Presentation click here Read More

Company Overview

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Latest ASX Announcements

Media Releases

ASX Share Price

Market Cap:
Price Delay ~20min
Amplia Therapeutics recognises and respects First Nations People and welcomes the work of all those who strive for health equality in Australia